责任编辑：小浪快报 资料显示，上海建发致新医疗科技集团股份有限公司位于上海市杨浦区杨树浦路288号9层，成立日期 2010年8月30日，上市日期2025年9月25日，公司主营业务涉及从事医疗器械直销及分销业务,并为终端 医院提供医用耗材集约化运营(SPD)服务。主营业务收入构成为：血管介入55.61%，外科器械21.46%， 检验试剂(IVD)13.05%，医疗设备6.24%，其他医疗器械2.79%，SPD及其他服务0.63%，其他(补 充)0.23%。 截至11月30日，建发致新股东户数3.02万，较上期减少20.40%；人均流通股1667股，较上期增加 25.63%。2025年1月-9月，建发致新实现营业收入148.61亿元，同比增长10.18%；归母净利润2.30亿元， 同比增长45.01%。 12月22日，建发致新涨0.09%，成交额1.53亿元。两融数据显示，当日建发致新获融资买入额1106.16万 元，融资偿还1248.55万元，融资净买入-142.39万元。截至12月22日，建发致新融资融券余额合计1.23 亿元。 融资方面，建发致新当日融资买入1106.16万元。当前融资余额1.23亿元，占流 ...

Core Viewpoint - The company Jianfa Zhixin has shown a slight decline in stock price, with a trading volume of 327 million yuan and a net financing inflow of 1.69 million yuan on November 25, indicating ongoing investor interest despite the minor price drop [1]. Financing Summary - On November 25, Jianfa Zhixin had a financing buy-in amount of 27.29 million yuan, with a total financing balance of 96.47 million yuan, representing 5.81% of its market capitalization [1]. - The company reported no short-selling activity on the same day, with a short-selling balance of 0 yuan [1]. Business Performance - As of September 30, Jianfa Zhixin had 38,000 shareholders, an increase of 151.60% from the previous period, while the average number of circulating shares per shareholder decreased by 60.25% [2]. - For the period from January to September 2025, the company achieved a revenue of 14.861 billion yuan, reflecting a year-on-year growth of 10.18%, and a net profit attributable to shareholders of 230 million yuan, which is a 45.01% increase year-on-year [2]. Company Overview - Jianfa Zhixin Medical Technology Group Co., Ltd. was established on August 30, 2010, and is located in Yangpu District, Shanghai. The company specializes in the direct sales and distribution of medical devices and provides centralized operation services for medical consumables to hospitals [1]. - The main revenue sources for the company include vascular intervention (55.61%), surgical instruments (21.46%), in vitro diagnostic reagents (13.05%), medical equipment (6.24%), and other medical devices (2.79%) [1].

Group 1 - On November 17, Jianfa Zhixin's stock price dropped by 3.44%, with a trading volume of 481 million yuan [1] - The financing data shows that on the same day, Jianfa Zhixin had a financing purchase amount of 43.37 million yuan and a financing repayment of 49.50 million yuan, resulting in a net financing outflow of 6.13 million yuan [1] - As of November 17, the total balance of margin trading for Jianfa Zhixin was 131 million yuan, accounting for 7.50% of its circulating market value [1] Group 2 - As of September 30, Jianfa Zhixin had 38,000 shareholders, an increase of 151.60% compared to the previous period, while the average circulating shares per person decreased by 60.25% to 1,327 shares [2] - For the period from January to September 2025, Jianfa Zhixin achieved an operating income of 14.861 billion yuan, representing a year-on-year growth of 10.18%, and a net profit attributable to shareholders of 230 million yuan, which is a year-on-year increase of 45.01% [2] Group 3 - Jianfa Zhixin, established on August 30, 2010, is located at 288 Yangshupu Road, Yangpu District, Shanghai, and is primarily engaged in the direct sales and distribution of medical devices, as well as providing centralized operation services for medical consumables to terminal hospitals [1] - The main revenue composition of Jianfa Zhixin includes: vascular intervention (55.61%), surgical instruments (21.46%), in vitro diagnostic reagents (13.05%), medical equipment (6.24%), other medical devices (2.79%), SPD and other services (0.63%), and others (0.23%) [1]

Core Viewpoint - The stock of Jianfa Zhixin has experienced fluctuations, with a recent decline of 2.00% and a year-to-date drop of 5.06%, despite a notable increase in revenue and profit for the year [1][2]. Group 1: Stock Performance - As of November 5, Jianfa Zhixin's stock price is 34.71 CNY per share, with a trading volume of 1.29 billion CNY and a turnover rate of 7.33%, resulting in a total market capitalization of 14.623 billion CNY [1]. - The stock has seen a net inflow of 1.6118 million CNY from main funds, with significant buying and selling activity in large orders [1]. - The stock has appeared on the "Dragon and Tiger List" 11 times this year, with the most recent appearance on November 4, showing a net buy of -10.334 million CNY [1]. Group 2: Company Overview - Jianfa Zhixin Medical Technology Group Co., Ltd. was established on August 30, 2010, and is located in Yangpu District, Shanghai [2]. - The company specializes in direct sales and distribution of medical devices, providing centralized operation services for medical consumables to hospitals [2]. - The revenue composition includes: vascular intervention (55.61%), surgical instruments (21.46%), in vitro diagnostic reagents (13.05%), medical equipment (6.24%), and other medical devices (2.79%) [2]. Group 3: Financial Performance - For the period from January to September 2025, Jianfa Zhixin achieved a revenue of 14.861 billion CNY, representing a year-on-year growth of 10.18%, and a net profit attributable to shareholders of 230 million CNY, with a year-on-year increase of 45.01% [2]. - As of September 30, the number of shareholders has increased by 151.60% to 38,000, while the average circulating shares per person decreased by 60.25% to 1,327 shares [2].

Core Viewpoint - On November 3, Jianfa Zhixin experienced a stock price increase of 3.98%, with a trading volume of 476 million yuan, indicating positive market sentiment towards the company [1]. Financing Summary - On the same day, Jianfa Zhixin recorded a financing buy-in amount of 31.04 million yuan, with a net financing buy of 2.80 million yuan after repayments of 28.24 million yuan [1]. - As of November 3, the total financing and securities balance for Jianfa Zhixin reached 97.58 million yuan, accounting for 5.75% of its market capitalization [1]. - There were no securities sold or repaid on that day, with a remaining securities balance of 0.00 shares [1]. Company Overview - Jianfa Zhixin Medical Technology Group Co., Ltd. was established on August 30, 2010, and is located at 288 Yangshupu Road, Yangpu District, Shanghai [1]. - The company specializes in the direct sales and distribution of medical devices and provides centralized operation services for medical consumables to terminal hospitals [1]. - The revenue composition of Jianfa Zhixin includes: vascular intervention (55.61%), surgical instruments (21.46%), in vitro diagnostic reagents (13.05%), medical equipment (6.24%), other medical devices (2.79%), centralized operation services (0.63%), and other (0.23%) [1]. Financial Performance - For the period from January to September 2025, Jianfa Zhixin achieved a revenue of 14.861 billion yuan, reflecting a year-on-year growth of 10.18% [2]. - The net profit attributable to the parent company was 230 million yuan, representing a significant year-on-year increase of 45.01% [2]. - As of September 30, the number of shareholders increased to 38,000, up by 151.60%, while the average circulating shares per person decreased by 60.25% to 1,327 shares [2].

Core Viewpoint - The stock of Jianfa Zhixin has shown significant trading activity, with a notable increase in share price and fluctuations in financing activities, indicating investor interest and potential growth in the medical technology sector [1][2]. Group 1: Stock Performance - On October 22, Jianfa Zhixin's stock rose by 7.19%, with a trading volume of 734 million yuan [1]. - The financing buy-in amount for Jianfa Zhixin on the same day was 49.23 million yuan, while the financing repayment was 59.83 million yuan, resulting in a net financing outflow of 10.60 million yuan [1]. - As of October 22, the total financing and securities balance for Jianfa Zhixin was 82.78 million yuan, accounting for 5.30% of its market capitalization [1]. Group 2: Company Overview - Jianfa Zhixin Medical Technology Group Co., Ltd. was established on August 30, 2010, and is located in Yangpu District, Shanghai [1]. - The company specializes in direct sales and distribution of medical devices and provides centralized operation services for medical consumables to hospitals [1]. - The revenue composition of Jianfa Zhixin includes: vascular intervention (55.61%), surgical instruments (21.46%), in vitro diagnostic reagents (13.05%), medical equipment (6.24%), other medical devices (2.79%), and centralized operation services (0.63%) [1]. Group 3: Financial Performance - For the period from January to June 2025, Jianfa Zhixin reported a revenue of 9.829 billion yuan, representing a year-on-year growth of 12.18% [2]. - The net profit attributable to shareholders for the same period was 137 million yuan, showing a year-on-year increase of 42.34% [2]. - As of September 25, the number of shareholders for Jianfa Zhixin reached 15,100, marking a significant increase of 301,860% compared to the previous period [2].

Core Insights - On October 13, Jianfa Zhixin experienced a decline of 1.30% with a trading volume of 276 million yuan [1] - The company reported a financing buy-in amount of 26.88 million yuan and a net financing buy-in of 12.41 million yuan on the same day [1][2] - As of October 13, the total financing and securities balance for Jianfa Zhixin was 85.27 million yuan, accounting for 6.34% of its market capitalization [1] Financing Summary - On October 13, Jianfa Zhixin had a financing buy-in of 26.88 million yuan, with a current financing balance of 85.27 million yuan [1] - The financing balance represents 6.34% of the company's circulating market value [1] Securities Summary - On October 13, there were no shares repaid or sold in the securities lending market, resulting in a balance of 0.00 yuan [1] - The securities lending balance was also reported as 0.00 shares [1] Company Overview - Jianfa Zhixin Medical Technology Group Co., Ltd. was established on August 30, 2010, and is located in Yangpu District, Shanghai [1] - The company specializes in direct sales and distribution of medical devices and provides centralized operation services for medical consumables to hospitals [1] - The revenue composition includes: vascular intervention (55.61%), surgical instruments (21.46%), in vitro diagnostic reagents (13.05%), medical equipment (6.24%), and other medical devices (2.79%) [1] Shareholder Information - As of September 25, Jianfa Zhixin had 15,100 shareholders, an increase of 301,860% compared to the previous period [2] - The average number of circulating shares per shareholder was 3,339 shares, with no change from the previous period [2] Financial Performance - For the first half of 2025, Jianfa Zhixin reported a revenue of 9.829 billion yuan, representing a year-on-year growth of 12.18% [2] - The net profit attributable to the parent company was 137 million yuan, showing a year-on-year increase of 42.34% [2]

Core Insights - On September 25, Jianfa Zhixin's stock surged by 418.58%, with a trading volume of 1.477 billion yuan [1] - The company recorded a net financing purchase of 47.1425 million yuan on the same day, with a total financing balance of 47.1425 million yuan, accounting for 2.56% of its market capitalization [1] - Jianfa Zhixin's main business includes direct sales and distribution of medical devices, with significant revenue contributions from vascular intervention (55.61%) and surgical instruments (21.46%) [1] Financing and Shareholder Information - As of September 25, Jianfa Zhixin had 15,100 shareholders, an increase of 301,860% compared to the previous period [2] - The average number of circulating shares per shareholder is 3,339 shares, showing no change from the previous period [2] Financial Performance - For the first half of 2025, Jianfa Zhixin achieved a revenue of 9.829 billion yuan, representing a year-on-year growth of 12.18% [2] - The net profit attributable to the parent company was 137 million yuan, reflecting a year-on-year increase of 42.34% [2]